Checkpoint Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

James Oliviero

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage	38.7%
CEO tenure	9.1yrs
CEO ownership	4.3%
Management average tenure	no data
Board average tenure	6.1yrs

Recent management updates

Recent updates

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Sep 20

Checkpoint: Strong Data, But Comes With Risks

Sep 08

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Aug 12

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

May 18

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Apr 18

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

Feb 15

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Jan 28

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Nov 26

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Oct 30

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Jul 17

It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year

Jun 02

The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It

Mar 11

Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?

Feb 06

Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?

Jan 27

CEO Compensation Analysis

How has James Oliviero's remuneration changed compared to Checkpoint Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$42m
Mar 31 2024	n/a	n/a	-US$52m
Dec 31 2023	US$2m	US$636k	-US$52m
Sep 30 2023	n/a	n/a	-US$54m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	n/a	n/a	-US$56m
Dec 31 2022	US$2m	US$594k	-US$63m
Sep 30 2022	n/a	n/a	-US$71m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$67m
Dec 31 2021	US$2m	US$540k	-US$57m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$31m
Mar 31 2021	n/a	n/a	-US$26m
Dec 31 2020	US$2m	US$515k	-US$23m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$22m
Dec 31 2019	US$2m	US$480k	-US$25m
Sep 30 2019	n/a	n/a	-US$28m
Jun 30 2019	n/a	n/a	-US$32m
Mar 31 2019	n/a	n/a	-US$33m
Dec 31 2018	US$2m	US$450k	-US$36m
Sep 30 2018	n/a	n/a	-US$31m
Jun 30 2018	n/a	n/a	-US$27m
Mar 31 2018	n/a	n/a	-US$27m
Dec 31 2017	US$645k	US$430k	-US$23m

Compensation vs Market: James's total compensation ($USD1.64M) is about average for companies of similar size in the US market ($USD1.48M).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James Oliviero (48 yo)

9.1yrs

Tenure

US$1,641,591

Compensation

Mr. James F. Oliviero, III, CFA has been the Chief Executive Officer and President of Checkpoint Therapeutics, Inc. since October 16, 2015 and also has been its Director since October 15, 2018. Mr. Olivier...

Board Members

Name	Position	Tenure	Compensation	Ownership
James Oliviero	President	6.1yrs	US$1.64m	4.31% $ 6.8m
Michael Weiss	Chairman of the Board	9.7yrs	US$110.00k	0.25% $ 393.7k
Lindsay Rosenwald	Non-Executive Director	10yrs	US$100.00k	0.29% $ 463.9k
Wayne Marasco	Chairman of Scientific Advisory Board	9.7yrs	no data	no data
Roy Steven Herbst	Member of Scientific Advisory Board	no data	no data	no data
Neil Herskowitz	Independent Director	9.3yrs	US$110.00k	0.26% $ 411.3k
Christian Béchon	Independent Director	6.1yrs	US$100.00k	0.25% $ 402.0k
Barry Salzman	Independent Director	8.8yrs	US$100.00k	0.26% $ 411.3k
Bruce Johnson	Member of Scientific Advisory Board	3.7yrs	no data	no data
F. Hodi	Member of Scientific Advisory Board	3.7yrs	no data	no data
Emily Ruiz	Member of Scientific Advisory Board	3.7yrs	no data	no data
David Miller	Member of Scientific Advisory Board	3.7yrs	no data	no data

6.1yrs

Average Tenure

63.5yo

Average Age

Experienced Board: CKPT's board of directors are considered experienced (6.1 years average tenure).

Checkpoint Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

President recently sold US$50k worth of stock

Checkpoint Therapeutics, Inc., Annual General Meeting, May 13, 2024

Insufficient new directors

Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director

Checkpoint Therapeutics, Inc. Announces Board Changes, Effective January 31, 2024

Checkpoint Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Recent updates

Checkpoint Therapeutics, Inc. Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Consensus revenue estimates increase by 11%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Checkpoint Therapeutics, Inc Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Price target increased by 19% to US$21.67

Checkpoint Therapeutics, Inc. announced a financing transaction

Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $12.000001 million.

President recently sold US$50k worth of stock

Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission

No longer forecast to breakeven

First quarter 2024 earnings released: US$0.32 loss per share (vs US$0.89 loss in 1Q 2023)

Checkpoint Therapeutics, Inc., Annual General Meeting, May 13, 2024

Insufficient new directors

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director

Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule

Checkpoint Therapeutics, Inc. Receives A Letter from Nasdaq Confirming the Company Was No Longer in Compliance with the Board Independence Rule

New major risk - Financial position

New major risk - Share price stability

Checkpoint Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000001 million.

Checkpoint Therapeutics, Inc. Announces Board Changes, Effective January 31, 2024

Consensus revenue estimates increase by 25%, EPS downgraded

U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer

Consensus revenue estimates increase by 19%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

First quarter 2023 earnings released: US$0.89 loss per share (vs US$1.98 loss in 1Q 2022)

Consensus revenue estimates increase by 41%

Price target decreased by 42% to US$33.50

Consensus revenue estimates decrease by 78%, EPS upgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$103

Checkpoint Therapeutics, Inc. Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Consensus forecasts updated

Forecast to breakeven in 2024

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.14 loss in 3Q 2021)

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint: Strong Data, But Comes With Risks

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Price target decreased to US$17.60

Checkpoint Therapeutics, Inc. Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Consensus forecasts updated

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Checkpoint Therapeutics Inc. Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Checkpoint Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

CFO, Corporate Secretary & Treasurer recently sold US$72k worth of stock

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

CFO, Corporate Secretary & Treasurer recently sold US$93k worth of stock

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Forecast to breakeven in 2024

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics, Inc. Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.087 loss in 3Q 2020)

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.09 loss in 2Q 2020)

Consensus revenue estimates fall to US$359.0k